Name: Ipamorelin
Brand: PeptidesDirect
SKU: PD-IPAMORELIN-10MG
Price: 41.99 EUR
Availability: InStock

Question 1

What is Ipamorelin?

Accepted Answer

Ipamorelin is a selective growth hormone secretagogue peptide that stimulates the pituitary gland. It is a pentapeptide (5 amino acids) studied for its highly selective action on growth hormone release without significantly affecting cortisol or prolactin levels.

Question 2

How should I store Ipamorelin?

Accepted Answer

Store lyophilized Ipamorelin at -20°C for long-term storage or at 2-8°C for short-term use. Once reconstituted, keep refrigerated at 2-8°C and use within 30 days. Protect from light.

Question 3

What purity is your Ipamorelin?

Accepted Answer

Every batch of Ipamorelin ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory, at a minimum purity of 98%. We do not run a lab ourselves: the manufacturer commissions this test, and we pass the report on unchanged, with an online verification link on the product page.

Question 4

How do I reconstitute Ipamorelin?

Accepted Answer

Add bacteriostatic water slowly along the inside wall of the vial. Gently swirl - never shake. Use 1-2 mL of bacteriostatic water. The peptide should dissolve quickly into a clear solution.

Question 5

How does ipamorelin actually work in the body?

Accepted Answer

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger a pulse of growth hormone release. In the founding pharmacology study, that action was highly selective: even at doses more than 200 times the growth-hormone-releasing dose, it did not raise ACTH or cortisol above GHRH-stimulated levels, and none of the growth hormone secretagogues tested, including ipamorelin, changed FSH, LH, prolactin, or TSH (Raun et al, Eur J Endocrinol 1998, PMID 9849822). What set ipamorelin apart from older, non-selective secretagogues like GHRP-6 and GHRP-2 was ACTH and cortisol specifically: those two did raise both hormones in the same experiments, ipamorelin did not. The mechanism has been shown in rat pituitary cells in vitro, anaesthetized rats, and conscious swine, not in a chronic human dosing study.

Question 6

What has ipamorelin actually been tested on, humans or just animals?

Accepted Answer

Ipamorelin's evidence base is mostly rat and swine pharmacology: studies characterizing its growth-hormone-releasing selectivity (Raun et al, PMID 9849822), glucocorticoid-induced bone loss in rats (Andersen et al, Growth Horm IGF Res 2001, PMID 11735244), glucocorticoid-induced muscle wasting in rats (Malmlof et al, Growth Horm IGF Res 1999, PMID 10629165), and a rat model of post-surgical bowel dysfunction (Venkova et al, J Pharmacol Exp Ther 2009, PMID 19289567). The one human clinical trial tested it as a treatment for postoperative ileus after bowel surgery, a randomized, double-blind, placebo-controlled Phase 2 study in 117 surgical patients (Beck et al, Int J Colorectal Dis 2014, PMID 25331030). No human trial has tested ipamorelin for muscle, bone, body composition, or anti-aging use, the purposes it is popularly discussed for online.

Question 7

What dose of ipamorelin did the studies actually use, and is there a real human dose?

Accepted Answer

In rats, the acute growth-hormone-release ED50 was about 80 nmol/kg (roughly 0.057 mg/kg), given as a single intravenous bolus; in conscious swine the ED50 was about 2.3 nmol/kg (roughly 1.6 micrograms/kg), also a single IV bolus (Raun et al, Eur J Endocrinol 1998, PMID 9849822). In the one human trial, adult patients recovering from bowel surgery received 0.03 mg/kg by intravenous infusion twice daily from postoperative day 1 through day 7 or hospital discharge, for postoperative ileus, not for growth hormone stimulation (Beck et al, Int J Colorectal Dis 2014, PMID 25331030). Those are the doses each study actually administered, for those specific research or surgical-recovery purposes. No human dosing protocol for growth-hormone-secretagogue use has been published for ipamorelin.

Question 8

Did ipamorelin actually work in the trials, and how fast?

Accepted Answer

In the acute pharmacology studies, a single intravenous dose raised growth hormone to a maximum of about 1,545 ng/mL in rats and about 65 ng/mL in swine, though the published data give the peak values without reporting the exact time course to peak (Raun et al, PMID 9849822). In the rat postoperative-ileus model, a single 1 mg/kg dose shortened the time to the first bowel movement after intestinal surgery, and repeated dosing over 2 days increased fecal output, food intake, and body weight gain (Venkova et al, PMID 19289567). In the human ileus trial, the result was negative: median time to tolerating a solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p = 0.15) (Beck et al, PMID 25331030).

Question 9

What side effects did people actually have with ipamorelin in the human trial?

Accepted Answer

The only study with systematic human safety data is the Phase 2 postoperative-ileus trial: treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin group versus 94.8 percent of the placebo group, so the rate was not higher than placebo, though the published report does not break down which specific adverse events occurred in each arm (Beck et al, Int J Colorectal Dis 2014, PMID 25331030). That trial enrolled patients recovering from bowel surgery on other medications, not healthy adults using ipamorelin alone, so those percentages describe a specific surgical population, not a general safety profile. The animal pharmacology studies (rat, swine) reported no adverse events, but those were acute, single-dose experiments designed to measure hormone release, not dedicated safety studies (Raun et al, PMID 9849822; Venkova et al, PMID 19289567).

Question 10

Is ipamorelin actually safe long term, or is that just not known yet?

Accepted Answer

There is no published long-term human safety study of ipamorelin: the one human trial ran for at most 7 days in surgical patients, not weeks or months of use in healthy adults (Beck et al, Int J Colorectal Dis 2014, PMID 25331030). There is no published human trial at all for the muscle, bone, body-composition, or anti-aging uses ipamorelin is popularly discussed for online, those uses rest on short rodent studies and acute human GH-secretion pharmacology, not on controlled human outcome data. No regulator has reviewed ipamorelin for any indication, and the one condition it was tested for in humans, postoperative ileus, did not meet its primary endpoint, so it was never advanced toward approval. No case reports of adverse events specific to ipamorelin were identified in the literature reviewed here.

Question 11

Is ipamorelin FDA approved, or is it just a research chemical?

Accepted Answer

No, ipamorelin has no FDA or EMA approval for any indication, and the only clinical trial that tested it in humans, a Phase 2 study for postoperative ileus, did not meet its primary endpoint and was not advanced (Beck et al, Int J Colorectal Dis 2014, PMID 25331030). It is sold here strictly as a research compound, not as a drug, supplement, or treatment.

Question 12

What does your own lab report (CoA) actually show for ipamorelin, and how do I check a batch?

Accepted Answer

Our current Ipamorelin batch (Red Cap, 10 mg labeled vial) carries a certificate of analysis from Janoshik Analytical showing 99.73 percent purity and 11.53 mg of measured active content. That report is commissioned by the manufacturer, not by us or an independent lab we paid for, and we publish it unedited on the product page. The same batch can be checked directly against Janoshik's own record at https://verify.janoshik.com/tests/86679_T9U1LKB242MK.

Question 13

How is ipamorelin different from GHRP-6 or GHRP-2?

Accepted Answer

All three are ghrelin-receptor agonists that trigger growth hormone release, but the founding pharmacology study found ipamorelin far more selective: at doses over 200 times its own GH-release ED50, it did not raise ACTH or cortisol above GHRH-stimulated levels, while GHRP-6 and GHRP-2 did raise both in the same experiments (Raun et al, Eur J Endocrinol 1998, PMID 9849822). GHRP-2 showed higher potency than ipamorelin in that study but lower maximal efficacy. None of these differences have been confirmed in a chronic human comparison trial, they come from acute animal and in vitro pharmacology.

Question 14

Does taking steroids cancel out ipamorelin's effects?

Accepted Answer

In rat studies, no. Methylprednisolone did not blunt the acute plasma growth hormone response to ipamorelin or to GHRH, and when the two were given together, ipamorelin significantly reduced the glucocorticoid-induced body weight loss and raised IGF-I levels compared to glucocorticoid alone (Malmlof et al, Growth Horm IGF Res 1999, PMID 10629165). A related rat study found the same combination increased periosteal bone formation about four-fold versus glucocorticoid alone, and improved calf-muscle tetanic tension (Andersen et al, Growth Horm IGF Res 2001, PMID 11735244). Both were short rat experiments (8 to 10 days, and 3 months respectively) from the same research group, not independently replicated or tested in humans.

Question 15

Is ipamorelin banned in sports, like by WADA?

Accepted Answer

Yes. Ipamorelin is named as an example under the growth hormone secretagogues (GHS) and growth hormone releasing peptides (GHRPs) class in the World Anti-Doping Agency's Prohibited List (category S2, Peptide Hormones, Growth Factors and Related Substances), which is banned at all times, in and out of competition. Anyone subject to WADA-code testing is prohibited from using it regardless of its legal availability for research purposes.

Question 16

Will ipamorelin show up on a drug test?

Accepted Answer

Not on the tests most people mean by a standard drug test. Routine employment or clinical urine panels screen for defined drug classes such as opioids, cannabinoids, cocaine, and amphetamines, they do not include peptide hormones or growth hormone secretagogues. Detecting ipamorelin requires a targeted mass-spectrometry assay of the kind WADA-accredited anti-doping laboratories use, not a routine screen, so competitive athletes should treat the WADA answer above as the relevant standard, not a workplace drug test.

Question 17

Is there any research on ipamorelin for women, or during pregnancy?

Accepted Answer

Some of the preclinical studies used only female rats, the glucocorticoid-induced bone-loss study and the glucocorticoid/catabolism study both used female Wistar rats (Andersen et al, PMID 11735244; Malmlof et al, PMID 10629165), while the postoperative-ileus rat model used only male rats (Venkova et al, PMID 19289567). None of the published rat or human studies report a sex-specific breakdown of growth hormone response or safety, and there is no published research on ipamorelin during pregnancy or breastfeeding. Anyone pregnant or breastfeeding is working from a complete absence of published safety data, not from a study that found it safe.

Question 18

Is ipamorelin the same as CJC-1295, since you sell them together?

Accepted Answer

No, they are different compounds with different mechanisms: ipamorelin selectively activates the ghrelin receptor (GHS-R1a) to trigger growth hormone release (Raun et al, Eur J Endocrinol 1998, PMID 9849822), while CJC-1295 is a separate peptide, a modified growth-hormone-releasing-hormone (GHRH) analogue that acts on the pituitary GHRH receptor. They are commonly sold and researched together as a blend, including on this site, because the two receptor pathways are pharmacologically distinct, but that specific combination has not been tested in a published human trial. Each compound's own evidence base, including its dosing and safety data, should be read separately, they are not two names for the same molecule.

Question 19

How much bacteriostatic water should be used to reconstitute Ipamorelin, and how long does the reconstituted solution stay stable, fridge versus freezer?

Accepted Answer

Our Ipamorelin vial is labeled 10 mg. A common convention for a vial this size is 1 to 3 mL of bacteriostatic water, added slowly down the inside wall of the vial and swirled gently, never shaken, until the solution runs clear. The volume chosen sets the resulting concentration, not the total peptide content or its chemical stability. Once reconstituted, the working solution is normally kept refrigerated at 2 to 8°C rather than frozen, and used within about 30 days; repeated freeze-thaw cycling is what stresses the peptide, more so than steady refrigeration. No published study has measured an exact shelf life for reconstituted Ipamorelin specifically, so this is standard peptide-handling practice, not a study finding.

Question 20

How does Ipamorelin compare to Sermorelin, the other major growth-hormone-releasing peptide?

Accepted Answer

They work through two different receptors that both end up triggering growth hormone release from the pituitary. Sermorelin is a GHRH(1-29) analogue: it binds the GHRH receptor, the same pathway the body's own growth-hormone-releasing hormone uses. Ipamorelin binds a separate target, the ghrelin receptor (GHS-R1a), acting as a ghrelin mimetic instead. The founding Ipamorelin pharmacology study used GHRH-stimulated hormone levels as its own reference point and found Ipamorelin more selective: it did not raise ACTH or cortisol above what GHRH produced, and did not change FSH, LH, prolactin or TSH (Raun et al, Eur J Endocrinol 1998, PMID 9849822). Sermorelin carries the deeper human trial history of the two; Ipamorelin's evidence is mostly rat and swine pharmacology plus one human trial for an unrelated indication. No published study has compared the two peptides directly, head to head.

Question 21

Has ipamorelin been tested for fat loss in humans, or do published studies mainly measure GH and IGF-I?

Accepted Answer

The published research on ipamorelin measures growth hormone release and, in the glucocorticoid studies, IGF-I, not fat mass. The founding pharmacology study tracked plasma GH and hormone selectivity in rats and swine, not body composition (Raun et al, Eur J Endocrinol 1998, PMID 9849822); the rat studies that did measure IGF-I and body weight examined glucocorticoid-induced muscle wasting and bone loss, not fat loss in healthy animals (Malmlof et al, PMID 10629165; Andersen et al, PMID 11735244). The one human trial measured recovery from bowel surgery (Beck et al, PMID 25331030). The idea that raising GH and IGF-1 drives fat loss comes from the broader growth-hormone literature, not from a dedicated ipamorelin fat-loss trial, and that specific link has not been tested for this compound in humans.

Question 22

Does ipamorelin increase appetite or hunger, since it activates the same ghrelin receptor that drives hunger signalling?

Accepted Answer

The Raun et al 1998 selectivity study measured ACTH, cortisol, and prolactin, not appetite or hunger; ipamorelin was shown not to raise ACTH or cortisol above GHRH-stimulated levels, and it did not raise prolactin either, but hunger itself was not a measured endpoint (Raun et al, Eur J Endocrinol 1998, PMID 9849822). Ipamorelin does activate the ghrelin receptor, the same receptor ghrelin uses to stimulate hunger, so a hunger effect is biologically plausible, but no published ipamorelin study has tracked food intake or appetite in healthy humans. The one rat food-intake data point that exists comes from a postoperative-ileus model in sick animals, not a study of appetite in health (Venkova et al, PMID 19289567). Whether ipamorelin meaningfully affects human appetite has not been established either way.

Question 23

Does ipamorelin affect insulin sensitivity or blood glucose, based on the published research?

Accepted Answer

Growth hormone itself is well established in the broader endocrinology literature as counter-regulatory to insulin: sustained, supraphysiologic GH levels raise blood glucose and reduce insulin sensitivity, which is part of why conditions like acromegaly carry a documented diabetes risk. Ipamorelin works by triggering a GH pulse, so that general GH-insulin relationship is the relevant background, but none of the published ipamorelin studies measured glucose or insulin sensitivity as an endpoint: the pharmacology studies tracked GH release (Raun et al, PMID 9849822), and the one human trial tracked recovery from bowel surgery, not metabolic markers (Beck et al, PMID 25331030). Dedicated glucose or insulin data for ipamorelin itself, especially with repeated or long-term dosing, has not been published.

Question 24

Is there a physiological link between time of day (like sleep) and growth hormone release that's relevant to how ipamorelin works?

Accepted Answer

This site does not provide dosing schedules or timing instructions for using ipamorelin on a person; it is sold strictly for in-vitro research use. What the broader growth-hormone literature does establish is a well-known physiological pattern: the body's largest natural GH pulse occurs during deep sleep, independent of any secretagogue. The pharmacology studies behind ipamorelin measured acute GH release after a single dose in rats and swine, not a comparison of morning versus evening administration, and no published ipamorelin study has tested time of day as a variable (Raun et al, Eur J Endocrinol 1998, PMID 9849822). Any specific timing protocol referenced elsewhere is not something the underlying research established.

Question 25

Does the body build tolerance to ipamorelin with continuous daily use, or does the GH-releasing effect stay consistent over time, based on the published research?

Accepted Answer

Receptor desensitization with repeated agonist exposure is a general pharmacological phenomenon documented for many G-protein-coupled receptors, including, in some animal studies, ghrelin-receptor agonists, but no published ipamorelin study has specifically tested whether its GH-releasing effect declines with continuous daily dosing over weeks or months. The pharmacology studies behind ipamorelin were acute, single or short-course dosing in rats and swine (Raun et al, PMID 9849822); the rat glucocorticoid studies ran 8 to 10 days and 3 months respectively with GH-axis effects still measurable at the end (Malmlof et al, PMID 10629165; Andersen et al, PMID 11735244); and the one human trial ran at most 7 days (Beck et al, PMID 25331030). Whether tolerance develops with longer human use has not been studied.

Question 26

Does ipamorelin improve sleep quality, based on published research, or is that an inference from GH's general role in sleep architecture?

Accepted Answer

These are two different claims. It is well established in the broader sleep and endocrinology literature that the body's largest natural growth hormone pulse occurs during deep, slow-wave sleep. It is a separate and much weaker claim that artificially raising GH with a secretagogue like ipamorelin then improves subjective sleep quality, and that specific link has not been tested in a published ipamorelin study. The pharmacology research behind ipamorelin measured hormone release, not sleep architecture or sleep-quality outcomes (Raun et al, Eur J Endocrinol 1998, PMID 9849822), and the one human trial tracked recovery from bowel surgery, not sleep (Beck et al, PMID 25331030). Any sleep-quality benefit attributed to ipamorelin is an inference from GH physiology, not a finding from ipamorelin research itself.

Question 27

Where should I keep the vial before I reconstitute it?

Accepted Answer

In the fridge, from the day it arrives. This is the step people skip most often, because a sealed freeze-dried vial looks robust enough to leave in a drawer. The dry cake in these GHRH-family vials is thin and porous, and warmth combined with humidity makes it slump and densify. A collapsed cake then dissolves slowly or incompletely and can leave a haze or floating particles when you finally add water, even when the powder itself still assays perfectly. So put the vial in the fridge at 2 to 8 degrees Celsius on the day the parcel arrives, or in the freezer at -20 degrees if it will sit unused for more than a couple of weeks, and keep it dark either way. Let it come back to room temperature before you add water. Once reconstituted it stays in the fridge and never goes into the freezer, because freeze-thaw cycles are harder on a dissolved peptide than steady cold. The few days in transit at ambient temperature are expected and fine; it is the weeks afterwards that decide how well it dissolves.

Question 28

Does the bacteriostatic water I use actually matter?

Accepted Answer

More than most people expect, and the reason is the specification rather than the brand. Bacteriostatic water is permitted a wide window: the USP range is pH 4.5 to 7.0, so two bottles that both say 0.9% benzyl alcohol can sit at opposite ends of it. Most labels state the benzyl alcohol and nothing else, so you cannot tell where yours sits. That matters because a peptide is least soluble near its own isoelectric point, and a water that drifts to one edge of the range can push a sensitive peptide toward it, which shows up as haze or particles that no amount of swirling fixes. We know this first-hand: one of our own past water batches measured pH 3.8 on a meter, below the permitted floor, and it turned GLP-1 peptides milky regardless of technique. Our own bacteriostatic water now comes from a European manufacturer whose batches run pH 6.2 to 6.4, with the measured value for the specific batch stated on its certificate rather than just a pass mark. Whichever water you use, take a freshly opened vial, keep it at room temperature and out of the light, and do not reuse a bottle that has been open for months.

Question 29

Does unrefrigerated shipping affect the quality of this product?

Accepted Answer

No. This product ships as a lyophilized (freeze-dried) powder in a sealed vial. Freeze-drying removes the water that drives peptide degradation, so the dry powder remains stable at room temperature for extended periods, longer than any normal parcel transit. Ambient shipping is standard practice across the peptide industry, and a peer-reviewed study reported months of room-temperature stability for a lyophilized therapeutic peptide (teriparatide, PMID 26620825). For comparison, FDA labeling allows an Ozempic (semaglutide) pen, after first use, to be kept out of the fridge for 56 days at 15 to 30°C, and a Mounjaro (tirzepatide) pen for up to 21 days at up to 30°C, even though these are ready-mixed solutions rather than sealed dry powder. Store the sealed vial in the fridge or freezer for long-term storage, and always refrigerate after reconstitution.

Question 30

Does CJC-1295/Ipamorelin measurably raise IGF-1 in the published studies, by how much and for how long, and why can an individual IGF-1 reading barely move?

Accepted Answer

The only human fold-change data come from CJC-1295 WITH DAC, the long-acting form we do not sell: a single dose raised mean GH 2 to 10-fold for about 6 days and IGF-1 1.5 to 3-fold for 9 to 11 days (PMID 16352683). No dedicated human trial exists for the no-DAC form in this product, and Ipamorelin's single human trial measured post-surgical bowel recovery, never GH or IGF-1; its GH-release data are rat and swine pharmacology (PMID 9849822). So 'does the blend raise IGF-1 in humans, and by how much' has literally never been measured. Why an individual reading can still barely move even if the biology works: the trial reported only group means from a small study, and no study has characterized the spread of individual responses or whether baseline GH status predicts the response. On top of that, IGF-1 measurement itself is noisy between laboratories: the same serum samples measured in 5 labs varied with a mean coefficient of variation of about 26 percent (PMID 17323843); IGF-1 also declines steadily with age along a documented curve from a 15,014-subject reference study (PMID 24606072), so an age-typical value can read as 'low' against a young-adult range. A single IGF-1 draw is a weak instrument: as a screening test for GH deficiency it performed barely better than chance (AUC 0.517, PMID 34373538). One number, one lab, one time point cannot verify or falsify a research compound.

Question 31

What happens to GH/IGF-1 levels, strength, sleep, or muscle after stopping a CJC-1295/Ipamorelin cycle, and is there published data on anything reversing?

Accepted Answer

No controlled human study has followed anyone after stopping CJC-1295 (either form) or Ipamorelin, so the after-stopping question has no measured answer for GH, IGF-1, strength, muscle or sleep. The closest documented curve is from the DAC form we do not sell: after multiple doses, mean IGF-1 was still above baseline at 28 days, when the trial's observation window simply ended, so even that study never captured a full return to baseline (PMID 16352683). For the no-DAC form in this product there is no dedicated human pharmacokinetic study at all, and Ipamorelin's one human trial (post-surgical bowel recovery, IV dosing, PMID 25331030) measured no hormones. Equally important: no human trial of either compound, in any form, ever measured strength, lean mass or sleep as an outcome even DURING use, so 'do the gains reverse' presumes on-drug effects that were never quantified in the first place. The one adjacent literature that does exist, withdrawal studies of exogenous recombinant GH in diagnosed GH-deficient patients, describes a different molecule in a different population and does not transfer. What physiology does say: these peptides work by stimulating the body's own pulsatile GH release rather than replacing it, and no published data show suppression of the axis after stopping, but absence of data is the operative phrase, not evidence of a soft landing.

Question 32

Is facial flushing or a head-rush feeling right after a CJC-1295/Ipamorelin injection documented in the studies, how strong can it be, and does a weak flush mean a weak product?

Accepted Answer

Flushing is genuinely documented, but for a different molecule than most people assume: in the CJC-1295 WITH DAC trial, transient flushing and warmth shortly after injection were among the reported adverse events, and two subjects experienced transient dizziness and hypotension after their first injection, notably at the LOWEST dose in that study arm, both resolving without treatment (PMID 16352683, full text). Tachycardia or a pounding heart does not appear anywhere in that trial's reporting; the cardiovascular findings were hypotension-direction, not racing-heart-direction. For the related GHRH peptide sermorelin, published data describe transient facial warmth or flushing typically resolving within minutes (PMID 18031173). No trial has ever dosed the exact no-DAC CJC-1295/Ipamorelin combination in this product, and ipamorelin's one human trial reported only aggregate adverse-event rates with no flush breakdown (PMID 25331030), so blend-specific incidence and intensity numbers do not exist. The product-quality inference fails in both directions: no published source validates flush strength as an indicator of dose, purity or authenticity, and the trial data themselves show the response varies by person and dose without tracking potency. The verifiable quality signal remains the batch CoA. For completeness, the serious end of CJC-1295's clinical history is also on record: the DAC-form phase 2 programme was terminated after a participant death in 2006, with causality unconfirmed and the attending physician attributing it most likely to pre-existing coronary disease, as we document on the product page.

Question 33

Did any study test CJC-1295/Ipamorelin fasted versus fed, or morning versus before bed, and what does GH physiology say about glucose and GH release?

Accepted Answer

No published trial was identified testing fasted-versus-fed or time-of-day dosing for CJC-1295 (either form), ipamorelin, or the blend; the one human CJC-1295 study dosed the long-acting DAC form on fixed schedules (PMID 16352683), and ipamorelin's single human trial ran fixed post-surgical IV infusions with no meal or timing arms (PMID 25331030). The physiology behind the community's fasted-dosing rule is, however, genuinely documented, in related secretagogues: under a hyperglycemic clamp, the GH response to GHRH plus GHRP-6 dropped significantly compared with normal glucose (PMID 14693411), and a meal blunted hexarelin's GH response by about 40 percent while nearly abolishing the response to GHRH itself (PMID 10824712); the classic review literature lists glucose and free fatty acids among the established suppressors of stimulated GH release (PMID 9186261). Three limits keep this honest: all of that is GHRH/GHRP-class evidence, none of it was generated with the no-DAC CJC-1295 or ipamorelin molecules themselves; the clamp study was in type 2 diabetes patients with IV dosing, not healthy subcutaneous use; and no study was identified measuring whether the roughly 30-minute half-life of the no-DAC form we sell makes its response more or less sensitive to a recent meal. The bedtime logic rests on the documented fact that the largest natural GH pulse occurs in deep sleep, but as our existing FAQs note, no identified study has tested whether secretagogue timing around sleep changes any outcome. So: plausible physiology, borrowed from cousins, untested in these molecules.

Question 34

Why might CJC-1295/Ipamorelin disrupt sleep (waking at night) instead of the deep sleep people expect?

Accepted Answer

No measurement was identified: no controlled trial of either compound or the blend recording sleep continuity, wake-after-sleep-onset or any sleep-architecture endpoint, so both the deep-sleep promise and the 3-a.m.-wide-awake complaint rest on self-reports, which our FAQs document as genuinely running in both directions. What the adjacent physiology literature shows is more interesting than either camp assumes. The class mechanisms mostly point toward MORE deep sleep: GHRH itself enhanced slow-wave sleep in men (with an opposite, sleep-impairing pattern documented in women, PMID 17850984, one of the few sex-split findings in this field), and ghrelin, which stimulates the same receptor as ipamorelin, increased slow-wave sleep while reducing REM in human dosing studies (PMID 12388174, PMID 18329818). The route caveat cuts the other way: in mice, ghrelin delivered centrally promoted WAKEFULNESS while peripheral dosing did not change sleep (PMID 22815958), a reminder that receptor location decides the direction. Ipamorelin's celebrated selectivity (cortisol and ACTH responses not significantly different from GHRH stimulation) is swine pharmacology (PMID 9849822), never verified in humans, so a stress-axis explanation for bad nights can be neither invoked nor excluded. And our Mod GRF article documents an adjacent community pattern, transient nighttime flushing and warmth, that can itself wake people independent of any EEG effect. Net: the adjacent GHRH/ghrelin literature mostly points toward deeper sleep but tested none of these molecules, a documented sex difference and route dependence complicate it, individual divergence is unexplained, and no study of the fragmented-sleep phenomenon was identified for these compounds.

Ipamorelin

What is Ipamorelin

How it works

Often studied alongside

Documentation

Storage and stability

Reviews

Frequently Asked Questions

Technical data sheet

Frequently bought together

CJC-1295 (No DAC)

CJC-1295 (No-DAC)/Ipamorelin

IGF-1 LR3

Sermorelin

Bacteriostatic Water

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)

Graduated Measuring Syringe 1 mL 31G x 6 mm

Alcohol Prep Pads 30 x 65 mm

Peptide Storage Box (10 Compartments)

Peptide Vial Case 30 Slots